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Labeled
• multicentric Castleman disease
Off-Label
• coronavirus disease 2019 (COVID-19) † • severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection 
†
† Off-label indication
INVESTIGATIONAL USE: For adjunctive use in the treatment of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection†, the 
virus that causes coronavirus disease 2019 (COVID-19)†
Intravenous dosage
• Adults
Efficacy has not been established. Due to a lack of clinical data, the National Institutes of
Health (NIH) COVID-19 treatment guidelines do not give recommendations for or against
the use of IL-6 receptor inhibitors, such as siltuximab.[65314] A single dose of 11 mg/kg via
intravenous infusion over 1 hour is being evaluated. In 1 study, a second dose could be
administered at the physician's discretion; a total of 5 patients received a second dose
[dosing interval: 2 days (n = 3/5), 3 days (n = 2/5)].[65194] [65223] [65224] [65227]
For the treatment multicentric Castleman disease (MCD) in patients who 
are human immunodeficiency virus (HIV)-negative and human 
herpesvirus-8 (HHV-8)-negative
NOTE: The FDA has designated siltuximab as an orphan drug for Castleman disease.
Intravenous dosage
• Adults
11 mg/kg IV over 1 hour every 3 weeks until treatment failure. Prior to starting siltuximab 
therapy, verify that the absolute neutrophil count is 1 x 109 cells/L or greater, the platelet 
count is 75 x 109 cells/L or greater, and the hemoglobin concentration is less than 17 
grams/dL. Interrupt the siltuximab infusion for mild or moderate infusion-related reactions.
[57062] The response (complete response (CR) plus partial response (PR)) rate with 
improvement or stabilization of disease-related symptoms for at least 18 weeks (primary 
endpoint) was significantly higher in patients who received siltuximab (n = 53; median 
duration of therapy, 19 cycles) compared with placebo (n = 26) (34% vs. 0%; p = 0.0012) 
for the treatment of multicentric Castleman disease in a multinational, randomized, double-
blind trial; the median duration of response was 383 days (range, 232 to 676 days). In this 
study, 55% of patients in the siltuximab arm had received prior systemic therapy. During 
the study, all patients received best supportive care specified by institutional guidelines. 
The response rates (evaluated by independent review using modified Cheson criteria) 
were 39% (CR, n = 2; PR, n = 18) and 4% (PR, n = 1) in the siltuximab and placebo arms, 
respectively (p = 0.0022); the time to response was 155 days (range, 44 to 742 days) in 
patients who received siltuximab. The durable symptomatic response rates (based on a 
disease-related overall symptom score evaluated by investigators) were 57% (n = 30) and 
19% (n = 5) in the siltuximab and placebo arms, respectively (p = 0.0018); the time to 
response was 170 days (range, 67 to 274 days) in patients who received siltuximab. Of 
note, no patients with the hyaline vascular disease subtype achieved a durable tumor and 
symptomatic response evaluated by independent review. At a median follow-up of 422 
days (range, 55 to 1,051 days), the median time to treatment failure was not reached in 
the siltuximab arm and was 134 days in the placebo arm (p = 0.0084). The 1-year overall 
survival rate was 100% and 92% in the siltuximab and placebo arms, respectively.[59439]
Therapeutic Drug Monitoring
Management of Treatment-Related Toxicity
Hematologic Toxicity
Verify that the absolute neutrophil count (ANC) is 1 x 109 cells/L or greater, the platelet count is 
50 x 109 cells/L or greater, and the hemoglobin concentration is less than 17 g/dL prior to giving 
the next siltuximab dose. Delay therapy until the hematologic criteria are met; do not reduce the 
siltuximab dose.[57062]
Maximum Dosage Limits
• Adults 
11 mg/kg IV.
• Geriatric 
11 mg/kg IV.
• Adolescents 
Safety and efficacy have not been established.
• Children 
Safety and efficacy have not been established.
• Infants 
Safety and efficacy have not been established.
• Neonates 
Safety and efficacy have not been established.
Patients with Hepatic Impairment Dosing
No dosage adjustment is necessary in patients with mild (Child-Pugh class A) or moderate (Child-
Pugh class B) hepatic impairment. Siltuximab use has not been evaluated in patients with severe 
hepatic impairment (Child-Pugh class C).[57062]
Patients with Renal Impairment Dosing
No dosage adjustment is necessary in patients with renal impairment (creatinine clearance of 15 to 
90 mL/min). Siltuximab use has not been evaluated sufficiently in patients with end-stage renal 
disease.[57062]
† Off-label indication
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How Supplied
Siltuximab Lyophilisate for solution for injection
Sylvant 100mg Powder for Injection (57894-0420) (EUSA Pharma (US) LLC) 
Sylvant 100mg Powder for Injection (57894-0420) (Janssen Biotech, Inc.) (off market)
Sylvant 400mg Powder for Injection (57894-0421) (EUSA Pharma (US) LLC) 
Sylvant 400mg Powder for Injection (57894-0421) (Janssen Biotech, Inc.) (off market)
Description/Classification
Description
Siltuximab is an interleukin-6 antagonist indicated for the treatment of adult patients with 
multicentric Castleman disease who are human immunodeficiency virus-negative and human 
herpesvirus-8-negative. Monitor patients for signs and symptoms of infection; do not start 
siltuximab in patients with a severe active infection. Severe infusion-related reactions may occur; 
therefore, administer siltuximab in a setting that provides resuscitation equipment, medication, and 
personnel trained to provide resuscitation.[57062]
Updates for coronavirus disease 2019 (COVID-19):
Due to a lack of clinical data, the National Institutes of Health (NIH) COVID-19 treatment 
guidelines do not give recommendations for or against the use of IL-6 receptor inhibitors, such as 
siltuximab.[65314] Based on preliminary data from a study of another IL-6 receptor antibody, 
studies have begun to evaluate the use of siltuximab for COVID-19.[65194][65223][65224][65227]
Classifications
• Antineoplastic and Immunomodulating Agents
◦ Antineoplastics
◾ Antineoplastic Monoclonal Antibodies
◾ Immunomodulatory Monoclonal Antibodies
◾ Monoclonal Antibodies that Target Interleukin 6 (IL-6)
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Administration Information
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Route-Specific Administration
Injectable Administration
Visually inspect parenteral products for particulate matter and discoloration prior to administration 
whenever solution and container permit.
Intravenous Administration
Reconstitution:
• Allow the lyophilized vial(s) to come to room temperature over approximately 30 
minutes; vials should remain at room temperature for the duration of the preparation.
• A 21-gauge, 1 and 1/2 inch needle is recommended for preparation.
• Add 5.2 mL of Sterile Water for Injection to the 100-mg vial and 20 mL of Sterile 
Water for Injection to the 400-mg vial for a final vial concentration of 20 mg/mL.
• Gently swirl the reconstituted vial; do NOT shake or swirl vigorously.
• Allow the lyophilized powder to completely dissolve; powder should dissolve in less 
than 60 minutes.
• Storage following reconstitution: further dilute the vial contents within 2 hours of 
reconstitution.
Dilution:
• Withdraw the appropriate volume (mL) from the siltuximab 20 mg/mL vials for the 
calculated dose; discard any unused portion left in the vial.
• Dilute the calculated dose in 5% Dextrose Injection to a total infusion bag volume of 
250 mL; this may be achieved by withdrawing a volume equal to the calculated volume 
of siltuximab from a 250-mL bag of 5% Dextrose Injection.
• Gently invert the bag to mix the solution after slowing adding the calculated volume to 
the 5% Dextrose Injection solution.
• Infusion bags must be made of polyvinyl chloride (PVC), polyolefin, polypropylene, or 
polyethylene (PE); PE bottles may also be used.
• Storage after dilution: use within 4 hours after dilution.
Intravenous Infusion:
• Administer over 1 hour using an administration set lined with PVC, polyurethane, or 
PE containing a 0.2 micron inline polyethersulfone (PES) filter.
• Do not infuse concomitantly in the same IV line with other agents.
• Do not store any unused portion of the infusion solution.[57062]
Clinical Pharmaceutics Information
From Trissel's 2™ Clinical Pharmaceutics Database 
Siltuximab
1. pH Range
pH is approximately 5.2 (reconstituted).
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Adverse Reactions
• abdominal pain
• anaphylactoid reactions
• antibody formation
• back pain
• chest pain (unspecified)
• constipation
• cytokine release syndrome
• diarrhea
• dizziness
• edema
• edema
• erythema
• flushing
• gastroesophageal reflux
• GI perforation
• headache
• hypercholesterolemia
• hypertension
• hypertriglyceridemia
• hyperuricemia
• hyperuricemia
• hypotension
• hypotension
• infection
• infection
• infusion-related reactions
• infusion-related reactions
• maculopapular rash
• maculopapular rash
• nausea
• nephrotoxicity
• neutropenia
• oral ulceration
• palpitations
• pharyngitis
• pruritus
• psoriasis
• rash
• rash
• skin hyperpigmentation
• thrombocytopenia
• thrombocytopenia
• vomiting
• weight gain
• weight gain
• xerosis
Dermatologic adverse events that were reported more often in patients with multicentric 
Castleman disease who received siltuximab plus best supportive care (BSC) (n = 53) compared 
with placebo plus BSC (n = 26) in a randomized, phase 2 study included rash (28% vs. 12%; grade 
3 or 4, 2% vs. 0%), pruritus (28% vs. 8%), skin hyperpigmentation (4% vs. 0%), eczema (4% vs. 
0%), psoriasis (4% vs. 0%), and xerosis (4% vs. 0%). Rash included generalized rash, 
maculopapular rash, and pruritic rash.[57062]
Infection has been reported with siltuximab therapy. Monitor patients closely for signs or 
symptoms of infection during therapy. If an infection develops, start anti-infective therapy and 
hold siltuximab until the infection resolves. Lower respiratory tract infection (8% vs. 4%; grade 3 
or 4, 4% vs. 4%) and upper respiratory tract infection (26% vs. 15%; grade 3 or 4, 2% vs. 4%) 
were reported more often in patients with multicentric Castleman disease (MCD) who received 
siltuximab plus best supportive care (BSC) (n = 53) compared with placebo plus BSC (n = 26) in a 
randomized, phase 2 study. Additionally, naso-pharyngitis and urinary tract infection have been 
reported commonly in patients with MCD who received siltuximab in clinical studies.[57062]
Hematologic adverse events have been reported in patients who received siltuximab in clinical 
trials. Monitor complete blood counts prior to each dose for the first 12 months of therapy and 
then every 3 dosing cycles thereafter. After the first dose of therapy, ensure that the ANC is 1 x 
109 cells/L or greater, the platelet count is 50 x 109 cells/L or greater, and the hemoglobin 
concentration is less than 17 grams/dL prior to giving each siltuximab dose. Thrombocytopenia
was reported in 9% of patients who received siltuximab plus best supportive care (BSC) (n = 53) 
compared with 4% of patients with multicentric Castleman disease (MCD) who received placebo 
plus BSC (n = 26) in a randomized, phase 2 study; grade 3 or 4 thrombocytopenia occurred in 4% 
of siltuximab-treated patients. Additionally, neutropenia has been reported commonly in patients 
with MCD who received siltuximab in clinical studies.[57062]
Edema was reported in 26% of patients with multicentric Castleman disease who received 
siltuximab plus best supportive care (BSC) (n = 53) and 27% of patients who received placebo 
plus BSC (n = 26) in a randomized, phase 2 study; grade 3 or 4 edema occurred in 8% and 0% of 
patients, respectively.[57062]
Gastrointestinal (GI) adverse events such as abdominal pain, diarrhea, gastroesophageal reflux
disease, nausea, mouth/oral ulceration, and vomiting have been reported commonly in patients 
with multicentric Castleman disease (MCD) who received siltuximab in clinical studies. 
Additionally, GI perforation has been reported with siltuximab use. Promptly evaluate patients 
who have symptoms suggestive of GI perforation. Constipation (8% vs. 4%) and oropharyngeal 
pain (8% vs. 4%) were reported more often in patients with MCD who received siltuximab plus 
best supportive care (BSC) (n = 53) compared with placebo plus BSC (n = 26) in a randomized, 
phase 2 study.[57062]
Metabolic adverse events that were reported more often in patients with multicentric Castleman 
disease who received siltuximab plus best supportive care (BSC) (n = 53) compared with placebo 
plus BSC (n = 26) in a randomized, phase 2 study included hypertriglyceridemia (8% vs. 0%), 
hypercholesterolemia (4% vs. 0%), hyperuricemia (11% vs. 0%; grade 3 or 4, 2% vs. 0%) and 
weight gain (19% vs. 0%; grade 3 or 4, 2% vs. 0%).[57062]
Headache was reported in 8% of patients with multicentric Castleman disease (MCD) who 
received siltuximab plus best supportive care (BSC) (n = 53) compared with 4% of patients who 
received placebo plus BSC (n = 26) in a randomized, phase 2 study. Additionally, dizziness has 
been reported commonly in patients with MCD who received siltuximab in clinical studies.[57062]
Hypotension was reported in 4% of patients with multicentric Castleman disease (MCD) who 
received siltuximab plus best supportive care (BSC) (n = 53) compared with 0% of patients who 
received placebo plus BSC (n = 26) in a randomized, phase 2 study; grade 3 or 4 hypotension 
occurred in 2% of siltuximab-treated patients. Additionally, hypertension has been reported 
commonly in patients with MCD who received siltuximab in clinical studies.[57062]
Hypersensitivity reactions including anaphylactoid reactions have been reported with siltuximab 
therapy. One of 945 patients who received siltuximab in clinical studies experienced an 
anaphylactic reaction. If anaphylaxis, severe allergic reactions, or cytokine release syndrome
occurs during therapy, immediately stop the siltuximab infusion and do not resume therapy.[57062]
Infusion-related reactions were reported in 5.1% of patients who received single-agent siltuximab 
in clinical studies (n = 254); 0.8% of patients experienced grade 3 or 4 infusion-related reactions. 
Symptoms may include back pain, chest pain (unspecified) or discomfort, nausea, vomiting, 
flushing, erythema, and palpitations. Interrupt the siltuximab infusion for mild or moderate 
infusion-related reactions; therapy may be resumed at a lower infusion rate if the reaction 
resolves. The use of antihistamines, acetaminophen, and corticosteroids may be considered to help 
prevent or lessen infusion-related reactions. If the patient does not tolerate the siltuximab infusion 
despite the use of prophylactic medications, discontinue therapy. Infusion-related or 
hypersensitivity reactions were reported in 6.3% of patients treated with siltuximab in a long-term 
safety trial (n = 19); grade 3 or 4 reactions occurred in 1.3% of these patients.[57062
Antibody formation has been reported in 0.9% of patients who received siltuximab in clinical 
trials (n = 432). None of 243 patients who were evaluated using the antigen-bridging enzyme 
immunoassay method experienced an anti-therapeutic antibody (ATA) response. However, 4 of 
189 patients evaluated using the electrochemiluminescence-based immunoassay method tested 
positive for ATA; none of these patients had neutralizing antibodies.[57062]
Nephrotoxicity, specifically renal impairment, was reported in 8% of patients with multicentric 
Castleman disease who received siltuximab plus best supportive care (BSC) (n = 53) compared 
with 0% of patients who received placebo plus BSC (n = 26) in a randomized, phase 2 study.
[57062]
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Contraindications/Precautions
Absolute contraindications are italicized.
• breast-feeding 
• contraception requirements 
• diverticulitis 
• GI perforation 
• infants 
• infection 
• infusion-related reactions 
• neonates 
• neutropenia 
• peptic ulcer disease 
• pregnancy 
• reproductive risk 
• thrombocytopenia • vaccination 
Siltuximab use is contraindicated in patients who have had a severe hypersensitivity reaction to 
siltuximab or any components of the product. If anaphylaxis, severe allergic reactions, or cytokine 
release syndrome occur during therapy, immediately stop the siltuximab infusion and do not 
resume therapy. Only give siltuximab therapy in a setting that provides resuscitation equipment, 
medication, and personnel trained to provide resuscitation. Infusion-related reactions have been 
reported. Symptoms include back pain, chest pain/discomfort, nausea, vomiting, flushing, 
erythema, and palpitations. Interrupt the siltuximab infusion for mild or moderate infusion-related 
reactions; therapy may be resumed at a slower infusion rate if the reaction resolves. The use of 
antihistamines, acetaminophen, and corticosteroids may be considered to help prevent or lessen 
infusion-related reactions. If the patient does not tolerate the siltuximab infusion despite the use of 
prophylactic medications, discontinue therapy.[57062]
Siltuximab may mask signs and symptoms of infection (e.g., suppress fever and/or C-reactive 
protein (CRP) levels) or lower resistance to infection due to its immunosuppressive effects. Do not 
administer siltuximab to patients with severe infections until the infection resolves. Monitor 
patients closely for signs or symptoms of infection during therapy. If an infection develops during 
therapy, start anti-infective therapy and hold siltuximab until the infection resolves.[57062]
GI perforation has been reported with siltuximab therapy. Use siltuximab with caution in patients 
who may be at increased risk for GI perforation such as patients with diverticulitis or peptic ulcer 
disease. Promptly evaluate patients who have symptoms suggestive of GI perforation.[57062]
Hematologic adverse events (e.g., neutropenia and thrombocytopenia) have been reported with 
siltuximab therapy. Monitor complete blood counts prior to each dose for the first 12 months of 
therapy and then every 3 dosing cycles thereafter. Prior to starting siltuximab, ensure that the 
absolute neutrophil count (ANC) is 1 x 109 cells/L or greater, the platelet count is 75 x 109 cells/L 
or greater, and the hemoglobin concentration is less than 17 grams/dL. Ensure that the ANC is 1 x 
109 cells/L or greater, the platelet count is 50 x 109 cells/L or greater, and the hemoglobin 
concentration is less than 17 grams/dL prior to giving subsequent siltuximab doses.[57062]
Avoid vaccination with live vaccines in patients receiving siltuximab as IL-6 inhibition may 
interfere with the normal immune response to new antigens. Infants and neonates born to pregnant 
women who were treated with siltuximab may have an increased risk of infection; administer live 
vaccines to these patients with caution.[57062]
Based on findings in animal reproduction studies, siltuximab may cause fetal harm when 
administered during human pregnancy. There are no available data on siltuximab use in pregnant 
women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or 
fetal outcomes. Females of reproductive potential should avoid pregnancy during siltuximab 
therapy. Advise pregnant women of the potential fetal risk. Monoclonal antibodies appear to cross 
via the placenta. In cynomolgus monkey reproduction studies, siltuximab administration during 
organogenesis resulted in fetal serum concentrations that were similar to maternal concentrations 
at exposures above those occurring at the maximum recommended human dose of 11 mg/kg given 
every 3 weeks.[57062]
Counsel patients about the reproductive risk and contraception requirements during siltuximab 
treatment. Females of reproductive potential should avoid pregnancy and use effective 
contraception during and for 3 months after treatment with siltuximab.[57062]
Because of the potential for serious adverse reactions in the breast-fed child, including 
gastrointestinal perforation, breast-feeding is not recommended during situximab treatment and 
for 3 months after the last dose. There are no data on the presence of situximab in human milk, the 
effects on the breast-fed child, or the effects on milk production.[57062]
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Mechanism of Action
Siltuximab is a human-mouse chimeric monoclonal antibody that binds human interleukein-6 (IL-
6) and prevents the binding of IL-6 to both soluble and membrane-bound IL-6 receptors. IL-6 is a 
proinflammatory cytokine and overproduction of IL-6 has been linked to systemic manifestations 
in patients with multicentric Castleman disease (MCD).[57062]
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Pharmacokinetics
Siltuximab is administered intravenously (IV). The pharmacokinetic profile is a linear two-
compartment intravenous model with first-order elimination. Based on population 
pharmacokinetic analyses, the volume of distribution in a male patient weighing 70 kg was 4.5 L 
(coefficient of variance (CV), 20%), the clearance was 0.23 L/day (CV, 51%), and the terminal 
half-life after the first IV infusion was 20.6 days (range, 14.2 to 29.7 days).
Affected cytochrome P450 isoenzymes: CYP3A4
Siltuximab has not been evaluated in in vitro or in vivo drug interaction studies. However, 
inhibition of IL-6 signaling may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates. If siltuximab is administered with a CYP450 
substrate with a narrow therapeutic index (e.g., warfarin, cyclosporine, theophylline), therapeutic 
drug monitoring is recommended and a dose adjustment of the CYP450 substrate may be 
necessary. Use siltuximab with caution in patients who are receiving a CYP3A4 substrate in which 
a decrease in effectiveness would be undesirable (e.g., oral contraceptives, lovastatin, 
atorvastatin).[57062]
Route-Specific Pharmacokinetics
• Intravenous Route
In patients with multicentric Castleman disease, the steady-state mean Cmax value was 
332 micrograms (mcg)/mL (coefficient of variance (CV), 42%) and the mean Cmin 
value was 84 mcg/mL (CV, 78%) following siltuximab 11 mg/kg IV over 1 hour once 
every 3 weeks. Steady state levels are achieved by the sixth infusion following 
siltuximab IV once every 3 week dosing; it accumulates about 1.7-fold compared to a 
single dose. Siltuximab demonstrates approximately dose proportional 
pharmacokinetics over the dose range of 2.8 to 11 mg/kg.[57062]
Special Populations
• Hepatic Impairment
Mild or moderate hepatic impairment did not significantly affect the apparent clearance 
of siltuximab in a population pharmacokinetic (PK) analysis (n = 377); the influence of 
severe hepatic impairment on the PK parameters of siltuximab has not been evaluated. 
In this analysis, 72 patients with mild pre-existing hepatic impairment (Child-Pugh 
class A) and 3 patients with moderate pre-existing hepatic impairment (Child-Pugh 
class B) were compared with 302 patients who had normal hepatic function.[57062]
• Renal Impairment
Renal impairment did not significantly affect the apparent clearance of siltuximab in a 
population pharmacokinetic (PK) analysis (n = 377); the influence of end-stage renal 
disease (ESRD) on the PK parameters of siltuximab cannot be determined because 
only 1 patient had ESRD. In this analysis, 122 patients with mild pre-existing renal 
impairment (creatinine clearance (CrCl), 60 to 89 mL/min), 75 patients with moderate 
pre-existing renal impairment (CrCl, 30 to 59 mL/min), and 3 patients with severe pre-
existing renal impairment (CrCl, 15 to 29 mL/min) were compared with 176 patients 
who had normal renal function (CrCl, 90 mL/min or greater).[57062]
• Geriatric
Age (range, 18 to 85 years) did not affect siltuximab exposure in a population 
pharmacokinetic analysis (n = 378).[57062]
• Gender Differences
Gender did not affect siltuximab exposure in a population pharmacokinetic analysis 
(females, n = 175; males, n = 203).[57062]
• Obesity
Weight correlated with siltuximab clearance in a population pharmacokinetic analysis 
(n = 378); therefore, weight-based dosing is appropriate.[57062]
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Pregnancy/Breast-feeding
Pregnancy
Based on findings in animal reproduction studies, siltuximab may cause fetal harm when 
administered during human pregnancy. There are no available data on siltuximab use in pregnant 
women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or 
fetal outcomes. Females of reproductive potential should avoid pregnancy during siltuximab 
therapy. Advise pregnant women of the potential fetal risk. Monoclonal antibodies appear to cross 
via the placenta. In cynomolgus monkey reproduction studies, siltuximab administration during 
organogenesis resulted in fetal serum concentrations that were similar to maternal concentrations 
at exposures above those occurring at the maximum recommended human dose of 11 mg/kg given 
every 3 weeks.[57062]
Breast-Feeding
Because of the potential for serious adverse reactions in the breast-fed child, including 
gastrointestinal perforation, breast-feeding is not recommended during situximab treatment and 
for 3 months after the last dose. There are no data on the presence of situximab in human milk, the 
effects on the breast-fed child, or the effects on milk production.[57062]
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Interactions
Level 1 (Severe)
• Live Vaccines
Level 2 (Major)
• Clozapine
Level 3 (Moderate)
• Alfentanil
• Amlodipine; Atorvastatin
• Apixaban
• Atorvastatin
• Atorvastatin; Ezetimibe
• Belladonna Alkaloids; Ergotamine; 
Phenobarbital
• Caffeine; Ergotamine
• Carbamazepine
• Cisapride
• Cyclosporine
• Dextromethorphan; Quinidine
• Dienogest; Estradiol valerate
• Dihydroergotamine
• Drospirenone
• Drospirenone; Estradiol
• Drospirenone; Ethinyl Estradiol
• Drospirenone; Ethinyl Estradiol; 
Levomefolate
• Ergotamine
• Estradiol; Levonorgestrel
• Estradiol; Norethindrone
• Estradiol; Norgestimate
• Ethinyl Estradiol
• Ethinyl Estradiol; Desogestrel
• Ethinyl Estradiol; Ethynodiol Diacetate
• Ethinyl Estradiol; Etonogestrel
• Ethinyl Estradiol; Levonorgestrel
• Ethinyl Estradiol; Levonorgestrel; 
Ferrous bisglycinate
• Ethinyl Estradiol; Levonorgestrel; Folic 
Acid; Levomefolate
• Ethinyl Estradiol; Norelgestromin
• Ethinyl Estradiol; Norethindrone
• Ethinyl Estradiol; Norethindrone 
Acetate
• Ethinyl Estradiol; Norethindrone 
Acetate; Ferrous fumarate
• Ethinyl Estradiol; Norethindrone; 
Ferrous fumarate
• Ethinyl Estradiol; Norgestimate
• Ethinyl Estradiol; Norgestrel
• Ethosuximide
• Everolimus
• Ezetimibe; Simvastatin
• Fentanyl
• Fosphenytoin
• Leuprolide; Norethindrone
• Levonorgestrel
• Lovastatin
• Lovastatin; Niacin
• Mestranol; Norethindrone
• Niacin; Simvastatin
• Norethindrone
• Norgestrel
• Oral Contraceptives
• Phenytoin
• Pimozide
• Quinidine
• Rivaroxaban
• Segesterone Acetate; Ethinyl Estradiol
• Simvastatin
• Simvastatin; Sitagliptin
• Sirolimus
• Tacrolimus
• Theophylline, Aminophylline
• Thioridazine
• Tizanidine
• Warfarin
Alfentanil: (Moderate) Monitor for evidence of reduced effect if alfentanil coadministration with 
siltuximab is necessary; alfentanil dosage adjustment may be needed. Inhibition of IL-6 signaling 
by siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 
substrates with a narrow therapeutic index, such as alfentanil, may have fluctuations in drug levels 
and therapeutic effect when siltuximab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping siltuximab. In vitro, siltuximab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Alfentanil is a CYP3A4 substrate and a narrow 
therapeutic index drug. [57062]
Amlodipine; Atorvastatin: (Moderate) Caution is warranted in patients receiving siltuximab who 
are taking CYP3A4 substrates, such as atorvastatin, in which a decreased effect would be 
undesirable. Monitor the patient's lipid profile as clinically indicated and adjust treatment as 
necessary. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Apixaban: (Moderate) Monitor for a decrease in efficacy of apixaban if used with siltuximab. 
Until more data are available, consider using an anticoagulant without dependence on CYP450 
enzymes for metabolism (e.g., heparins, edoxaban). The formation of CYP450 enzymes may be 
suppressed by increased concentrations of cytokines such as IL-6 during chronic inflammation. It 
is expected that the activity of CYP450 enzymes could increase to normal concentrations during 
treatment with an IL-6 antagonist such as siltuximab; these effects on CYP450 enzyme activity 
may persist for several weeks after stopping siltuximab. In vitro, siltuximab has the potential to 
affect expression of multiple CYP enzymes [including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4]. Apixaban is a substrate for CYP3A4. [52739] [57062] [65210]
Atorvastatin: (Moderate) Caution is warranted in patients receiving siltuximab who are taking 
CYP3A4 substrates, such as atorvastatin, in which a decreased effect would be undesirable. 
Monitor the patient's lipid profile as clinically indicated and adjust treatment as necessary. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Atorvastatin; Ezetimibe: (Moderate) Caution is warranted in patients receiving siltuximab who are 
taking CYP3A4 substrates, such as atorvastatin, in which a decreased effect would be undesirable. 
Monitor the patient's lipid profile as clinically indicated and adjust treatment as necessary. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Belladonna Alkaloids; Ergotamine; Phenobarbital: (Moderate) Monitor for decreased efficacy of 
ergotamine if coadministration with siltuximab is necessary. Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 
substrates with a narrow therapeutic index, such as ergotamine, may have fluctuations in drug 
levels and therapeutic effect when siltuximab therapy is started or discontinued. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping siltuximab. In vitro, 
siltuximab has the potential to affect expression of multiple CYP enzymes, including CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Ergotamine is a CYP3A4 substrate and 
narrow therapeutic index drug. [57062]
Caffeine; Ergotamine: (Moderate) Monitor for decreased efficacy of ergotamine if 
coadministration with siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 substrates 
with a narrow therapeutic index, such as ergotamine, may have fluctuations in drug levels and 
therapeutic effect when siltuximab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping siltuximab. In vitro, siltuximab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Ergotamine is a CYP3A4 substrate and narrow 
therapeutic index drug. [57062]
Carbamazepine: (Moderate) Monitor carbamazepine concentrations and watch for decreased 
efficacy of carbamazepine if coadministration with siltuximab is necessary; adjust carbamazepine 
dosage as necessary. Inhibition of IL-6 signaling by siltuximab may restore CYP450 activities to 
higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, 
such as carbamazepine, may have fluctuations in drug levels and therapeutic effect when 
siltuximab therapy is started or discontinued. This effect on CYP450 enzyme activity may persist 
for several weeks after stopping siltuximab. In vitro, siltuximab has the potential to affect 
expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Carbamazepine is a substrate of both CYP1A2 and CYP3A4 and a 
narrow therapeutic index drug. [57062]
Cisapride: (Moderate) Monitor for decreased efficacy of cisapride if coadministration with 
siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may restore CYP450 activities 
to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, 
such as cisapride, may have fluctuations in drug levels and therapeutic effect when siltuximab 
therapy is started or discontinued. This effect on CYP450 enzyme activity may persist for several 
weeks after stopping siltuximab. In vitro, siltuximab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Cisapride is a CYP3A4 substrate and a narrow therapeutic index drug. [57062]
Clozapine: (Major) It is unclear if concurrent use of other drugs known to cause neutropenia (e.g., 
antineoplastic agents) increases the risk or severity of clozapine-induced neutropenia. Because 
there is no strong rationale for avoiding clozapine in patients treated with these drugs, consider 
increased absolute neutrophil count (ANC) monitoring and consult the treating oncologist. [28262]
Cyclosporine: (Moderate) Monitor cyclosporine levels and adjust the dose of cyclosporine as 
appropriate if coadministration with siltuximab is necessary. Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 
substrates with a narrow therapeutic index, such as cyclosporine, may have fluctuations in drug 
levels and therapeutic effect when siltuximab therapy is started or discontinued. This effect on 
CYP450 enzyme activity may persist for several weeks after stopping siltuximab. In vitro, 
siltuximab has the potential to affect expression of multiple CYP enzymes, including CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Cyclosporine is a CYP3A4 substrate and 
a narrow therapeutic index drug. [57062]
Dextromethorphan; Quinidine: (Moderate) Monitor quinidine levels and adjust the dose of 
quinidine as appropriate if coadministration with siltuximab is necessary. Inhibition of IL-6 
signaling by siltuximab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment. 
Therefore, CYP450 substrates with a narrow therapeutic index, such as quinidine, may have 
fluctuations in drug levels and therapeutic effect when siltuximab therapy is started or 
discontinued. This effect on CYP450 enzyme activity may persist for several weeks after stopping 
siltuximab. In vitro, siltuximab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Quinidine is a 
CYP3A4 substrate and narrow therapeutic index drug. [57062]
Dienogest; Estradiol valerate: (Moderate) Caution is warranted when siltuximab is used in patients 
taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be 
undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Dihydroergotamine: (Moderate) Monitor for decreased efficacy of dihydroergotamine if 
coadministration with siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 substrates 
with a narrow therapeutic index, such as dihydroergotamine, may have fluctuations in drug levels 
and therapeutic effect when siltuximab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping siltuximab. In vitro, siltuximab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Dihydroergotamine is a CYP3A4 substrate and 
narrow therapeutic index drug. [57062]
Drospirenone: (Moderate) Caution is warranted when siltuximab is used in patients taking 
CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be undesirable. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Drospirenone; Estradiol: (Moderate) Caution is warranted when siltuximab is used in patients 
taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be 
undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Drospirenone; Ethinyl Estradiol: (Moderate) Caution is warranted when siltuximab is used in 
patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would 
be undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Drospirenone; Ethinyl Estradiol; Levomefolate: (Moderate) Caution is warranted when siltuximab 
is used in patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased 
effect would be undesirable. Cytochrome P450s in the liver are down regulated by infection and 
inflammation stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling 
by siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ergotamine: (Moderate) Monitor for decreased efficacy of ergotamine if coadministration with 
siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may restore CYP450 activities 
to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, 
such as ergotamine, may have fluctuations in drug levels and therapeutic effect when siltuximab 
therapy is started or discontinued. This effect on CYP450 enzyme activity may persist for several 
weeks after stopping siltuximab. In vitro, siltuximab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Ergotamine is a CYP3A4 substrate and narrow therapeutic index drug. [57062]
Estradiol; Levonorgestrel: (Moderate) Caution is warranted when siltuximab is used in patients 
taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be 
undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Estradiol; Norethindrone: (Moderate) Caution is warranted when siltuximab is used in patients 
taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be 
undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Estradiol; Norgestimate: (Moderate) Caution is warranted when siltuximab is used in patients 
taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be 
undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethinyl Estradiol: (Moderate) Caution is warranted when siltuximab is used in patients taking 
CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be undesirable. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Ethinyl Estradiol; Desogestrel: (Moderate) Caution is warranted when siltuximab is used in 
patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would 
be undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethinyl Estradiol; Ethynodiol Diacetate: (Moderate) Caution is warranted when siltuximab is used 
in patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect 
would be undesirable. Cytochrome P450s in the liver are down regulated by infection and 
inflammation stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling 
by siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethinyl Estradiol; Etonogestrel: (Moderate) Caution is warranted when siltuximab is used in 
patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would 
be undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethinyl Estradiol; Levonorgestrel: (Moderate) Caution is warranted when siltuximab is used in 
patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would 
be undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethinyl Estradiol; Levonorgestrel; Ferrous bisglycinate: (Moderate) Caution is warranted when 
siltuximab is used in patients taking CYP3A4 substrates, such as oral contraceptives, in which a 
decreased effect would be undesirable. Cytochrome P450s in the liver are down regulated by 
infection and inflammation stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of 
IL-6 signaling by siltuximab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. 
The effect of siltuximab on CYP450 enzyme activity can persist for several weeks after stopping 
therapy. [57062]
Ethinyl Estradiol; Levonorgestrel; Folic Acid; Levomefolate: (Moderate) Caution is warranted 
when siltuximab is used in patients taking CYP3A4 substrates, such as oral contraceptives, in 
which a decreased effect would be undesirable. Cytochrome P450s in the liver are down regulated 
by infection and inflammation stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition 
of IL-6 signaling by siltuximab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. The effect of siltuximab on CYP450 enzyme activity can persist for several weeks after 
stopping therapy. [57062]
Ethinyl Estradiol; Norelgestromin: (Moderate) Caution is warranted when siltuximab is used in 
patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would 
be undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethinyl Estradiol; Norethindrone Acetate: (Moderate) Caution is warranted when siltuximab is 
used in patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased 
effect would be undesirable. Cytochrome P450s in the liver are down regulated by infection and 
inflammation stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling 
by siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethinyl Estradiol; Norethindrone Acetate; Ferrous fumarate: (Moderate) Caution is warranted 
when siltuximab is used in patients taking CYP3A4 substrates, such as oral contraceptives, in 
which a decreased effect would be undesirable. Cytochrome P450s in the liver are down regulated 
by infection and inflammation stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition 
of IL-6 signaling by siltuximab may restore CYP450 activities to higher levels leading to 
increased metabolism of drugs that are CYP450 substrates as compared to metabolism prior to 
treatment. The effect of siltuximab on CYP450 enzyme activity can persist for several weeks after 
stopping therapy. [57062]
Ethinyl Estradiol; Norethindrone: (Moderate) Caution is warranted when siltuximab is used in 
patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would 
be undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethinyl Estradiol; Norethindrone; Ferrous fumarate: (Moderate) Caution is warranted when 
siltuximab is used in patients taking CYP3A4 substrates, such as oral contraceptives, in which a 
decreased effect would be undesirable. Cytochrome P450s in the liver are down regulated by 
infection and inflammation stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of 
IL-6 signaling by siltuximab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. 
The effect of siltuximab on CYP450 enzyme activity can persist for several weeks after stopping 
therapy. [57062]
Ethinyl Estradiol; Norgestimate: (Moderate) Caution is warranted when siltuximab is used in 
patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would 
be undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethinyl Estradiol; Norgestrel: (Moderate) Caution is warranted when siltuximab is used in patients 
taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be 
undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Ethosuximide: (Moderate) Monitor for reduced efficacy of ethosuximide, monitor drug 
concentrations, and adjust the dose of ethosuximide as appropriate if coadministration with 
siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may restore CYP450 activities 
to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, 
such as ethosuximide, may have fluctuations in drug levels and therapeutic effect when siltuximab 
therapy is started or discontinued. This effect on CYP450 enzyme activity may persist for several 
weeks after stopping siltuximab. In vitro, siltuximab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Ethosuximide is a CYP3A4 substrate and narrow therapeutic index drug. [57062]
Everolimus: (Moderate) Monitor for clinical response in patients taking everolimus concurrently 
with siltuximab. For indications where therapeutic drug monitoring is appropriate, monitor 
everolimus trough concentrations and adjust the dose of everolimus accordingly. Inhibition of IL-6 
signaling by siltuximab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment. 
Therefore, CYP450 substrates with a narrow therapeutic index, such as everolimus, may have 
fluctuations in drug levels and therapeutic effect when siltuximab therapy is started or 
discontinued. This effect on CYP450 enzyme activity may persist for several weeks after stopping 
siltuximab. In vitro, siltuximab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Everolimus is a 
CYP3A4 substrate and narrow therapeutic index drug. [57062]
Ezetimibe; Simvastatin: (Moderate) Caution is warranted in patients receiving siltuximab who are 
taking CYP3A4 substrates, such as simvastatin, in which a decreased effect would be undesirable. 
Monitor the patient's lipid profile as clinically indicated and adjust treatment as necessary. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Fentanyl: (Moderate) Monitor for evidence of reduced pain control or opioid withdrawal if 
fentanyl coadministration with siltuximab is necessary; fentanyl dosage adjustment may be 
needed. Inhibition of IL-6 signaling by siltuximab may restore CYP450 activities to higher levels 
leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism 
prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as 
fentanyl, may have fluctuations in drug levels and therapeutic effect when siltuximab therapy is 
started or discontinued. This effect on CYP450 enzyme activity may persist for several weeks 
after stopping siltuximab. In vitro, siltuximab has the potential to affect expression of multiple 
CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 
Fentanyl is a CYP3A4 substrate and narrow therapeutic index drug. [57062]
Fosphenytoin: (Moderate) Monitor fosphenytoin concentrations and watch for decreased efficacy 
of fosphenytoin if coadministration with siltuximab is necessary; adjust fosphenytoin dosage as 
necessary. Inhibition of IL-6 signaling by siltuximab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, 
such as fosphenytoin, may have fluctuations in drug levels and therapeutic effect when siltuximab 
therapy is started or discontinued. This effect on CYP450 enzyme activity may persist for several 
weeks after stopping siltuximab. In vitro, siltuximab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Fosphenytoin is a substrate of both CYP2C9 and CYP2C19 and narrow therapeutic 
index drug. [57062]
Leuprolide; Norethindrone: (Moderate) Caution is warranted when siltuximab is used in patients 
taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be 
undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Levonorgestrel: (Moderate) Caution is warranted when siltuximab is used in patients taking 
CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be undesirable. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Live Vaccines: (Severe) Do not administer live vaccines to siltuximab recipients; no data are 
available regarding the risk of secondary transmission of infection by live vaccines in patients 
receiving siltuximab. Before initiation of siltuximab therapy, consider completion of all age 
appropriate vaccinations per current immunization guidelines. Siltuximab recipients may receive 
inactivated vaccines, but the immune response to vaccines or toxoids may be decreased. [43236]
[57062]
Lovastatin: (Moderate) Caution is warranted in patients receiving siltuximab who are taking 
CYP3A4 substrates, such as lovastatin, in which a decreased effect would be undesirable. Monitor 
the patient's lipid profile as clinically indicated and adjust treatment as necessary. Cytochrome 
P450s in the liver are down regulated by infection and inflammation stimuli, including cytokines 
such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may restore CYP450 
activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates as 
compared to metabolism prior to treatment. The effect of siltuximab on CYP450 enzyme activity 
can persist for several weeks after stopping therapy. [57062]
Lovastatin; Niacin: (Moderate) Caution is warranted in patients receiving siltuximab who are 
taking CYP3A4 substrates, such as lovastatin, in which a decreased effect would be undesirable. 
Monitor the patient's lipid profile as clinically indicated and adjust treatment as necessary. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Mestranol; Norethindrone: (Moderate) Caution is warranted when siltuximab is used in patients 
taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be 
undesirable. Cytochrome P450s in the liver are down regulated by infection and inflammation 
stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Niacin; Simvastatin: (Moderate) Caution is warranted in patients receiving siltuximab who are 
taking CYP3A4 substrates, such as simvastatin, in which a decreased effect would be undesirable. 
Monitor the patient's lipid profile as clinically indicated and adjust treatment as necessary. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Norethindrone: (Moderate) Caution is warranted when siltuximab is used in patients taking 
CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be undesirable. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Norgestrel: (Moderate) Caution is warranted when siltuximab is used in patients taking CYP3A4 
substrates, such as oral contraceptives, in which a decreased effect would be undesirable. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Oral Contraceptives: (Moderate) Caution is warranted when siltuximab is used in patients taking 
CYP3A4 substrates, such as oral contraceptives, in which a decreased effect would be undesirable. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Phenytoin: (Moderate) Monitor phenytoin concentrations and watch for decreased efficacy of 
phenytoin if coadministration with siltuximab is necessary; adjust phenytoin dosage as necessary. 
Inhibition of IL-6 signaling by siltuximab may restore CYP450 activities to higher levels leading 
to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to 
treatment. Therefore, CYP450 substrates with a narrow therapeutic index, such as phenytoin, may 
have fluctuations in drug levels and therapeutic effect when siltuximab therapy is started or 
discontinued. This effect on CYP450 enzyme activity may persist for several weeks after stopping 
siltuximab. In vitro, siltuximab has the potential to affect expression of multiple CYP enzymes, 
including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Phenytoin is a 
substrate of both CYP2C9 and CYP2C19 and narrow therapeutic index drug. [57062]
Pimozide: (Moderate) Monitor for an altered patient response to pimozide if coadministration with 
siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may restore CYP450 activities 
to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, 
such as pimozide, may have fluctuations in drug levels and therapeutic effect when siltuximab 
therapy is started or discontinued. This effect on CYP450 enzyme activity may persist for several 
weeks after stopping siltuximab. In vitro, siltuximab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Pimozide a substrate of both CYP2D6 and CYP3A4 and narrow therapeutic index drug. 
[57062]
Quinidine: (Moderate) Monitor quinidine levels and adjust the dose of quinidine as appropriate if 
coadministration with siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 substrates 
with a narrow therapeutic index, such as quinidine, may have fluctuations in drug levels and 
therapeutic effect when siltuximab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping siltuximab. In vitro, siltuximab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Quinidine is a CYP3A4 substrate and narrow 
therapeutic index drug. [57062]
Rivaroxaban: (Moderate) Monitor for a decrease in efficacy of rivaroxaban if used with 
siltuximab. Until more data are available, consider using an anticoagulant without dependence on 
CYP450 enzymes for metabolism (e.g., heparins, edoxaban). The formation of CYP450 enzymes 
may be suppressed by increased concentrations of cytokines such as IL-6 during chronic 
inflammation. It is expected that the activity of CYP450 enzymes could increase to normal 
concentrations during treatment with an IL-6 antagonist such as siltuximab; these effects on 
CYP450 enzyme activity may persist for several weeks after stopping siltuximab. In vitro, 
siltuximab has the potential to affect expression of multiple CYP enzymes [including CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4]. Rivaroxaban is a substrate for 
CYP3A4/5. [44854] [57062] [65210]
Segesterone Acetate; Ethinyl Estradiol: (Moderate) Caution is warranted when siltuximab is used 
in patients taking CYP3A4 substrates, such as oral contraceptives, in which a decreased effect 
would be undesirable. Cytochrome P450s in the liver are down regulated by infection and 
inflammation stimuli, including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling 
by siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates as compared to metabolism prior to treatment. The effect of 
siltuximab on CYP450 enzyme activity can persist for several weeks after stopping therapy. 
[57062]
Simvastatin: (Moderate) Caution is warranted in patients receiving siltuximab who are taking 
CYP3A4 substrates, such as simvastatin, in which a decreased effect would be undesirable. 
Monitor the patient's lipid profile as clinically indicated and adjust treatment as necessary. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Simvastatin; Sitagliptin: (Moderate) Caution is warranted in patients receiving siltuximab who are 
taking CYP3A4 substrates, such as simvastatin, in which a decreased effect would be undesirable. 
Monitor the patient's lipid profile as clinically indicated and adjust treatment as necessary. 
Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli, 
including cytokines such as interleukin-6 (IL-6). Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates as compared to metabolism prior to treatment. The effect of siltuximab on 
CYP450 enzyme activity can persist for several weeks after stopping therapy. [57062]
Sirolimus: (Moderate) Monitor sirolimus levels and adjust the dose of sirolimus as appropriate if 
coadministration with siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 substrates 
with a narrow therapeutic index, such as sirolimus, may have fluctuations in drug levels and 
therapeutic effect when siltuximab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping siltuximab. In vitro, siltuximab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Sirolimus is a CYP3A4 substrate and narrow 
therapeutic index drug. [57062]
Tacrolimus: (Moderate) Monitor tacrolimus levels and adjust the dose of tacrolimus as appropriate 
if coadministration with siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 substrates 
with a narrow therapeutic index, such as tacrolimus, may have fluctuations in drug levels and 
therapeutic effect when siltuximab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping siltuximab. In vitro, siltuximab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Tacrolimus is a CYP3A4 substrate and narrow 
therapeutic index drug. [57062]
Theophylline, Aminophylline: (Moderate) Monitor drug concentrations and watch for decreased 
efficacy of aminophylline or theophylline if coadministration with siltuximab is necessary; a 
dosage increase of these methylxanthines may be necessary. Inhibition of IL-6 signaling by 
siltuximab may restore CYP450 activities to higher levels leading to increased metabolism of 
drugs that are CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 
substrates with a narrow therapeutic index may have fluctuations in drug levels and therapeutic 
effect when siltuximab therapy is started or discontinued. This effect on CYP450 enzyme activity 
may persist for several weeks after stopping siltuximab. In vitro, siltuximab has the potential to 
affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. Aminophylline and Theophylline are CYP1A2 substrates and narrow 
therapeutic index drugs. [57062]
Thioridazine: (Moderate) Monitor for an altered patient response to thioridazine if 
coadministration with siltuximab is necessary. Inhibition of IL-6 signaling by siltuximab may 
restore CYP450 activities to higher levels leading to increased metabolism of drugs that are 
CYP450 substrates compared to metabolism prior to treatment. Therefore, CYP450 substrates 
with a narrow therapeutic index, such as thioridazine, may have fluctuations in drug levels and 
therapeutic effect when siltuximab therapy is started or discontinued. This effect on CYP450 
enzyme activity may persist for several weeks after stopping siltuximab. In vitro, siltuximab has 
the potential to affect expression of multiple CYP enzymes, including CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Thioridazine is a CYP2D6 substrate and narrow 
therapeutic index drug. [57062]
Tizanidine: (Moderate) Monitor for reduced efficacy of tizanidine if coadministered with 
siltuximab. Inhibition of IL-6 signaling by siltuximab may restore CYP450 activities to higher 
levels leading to increased metabolism of drugs that are CYP450 substrates compared to 
metabolism prior to treatment. Therefore, CYP450 substrates with a narrow therapeutic index, 
such as tizanidine, may have fluctuations in drug levels and therapeutic effect when siltuximab 
therapy is started or discontinued. This effect on CYP450 enzyme activity may persist for several 
weeks after stopping siltuximab. In vitro, siltuximab has the potential to affect expression of 
multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4. Tizanidine is a CYP1A2 substrate and narrow therapeutic index drug. [57062]
Warfarin: (Moderate) Monitor the INR if siltuximab is coadministered with warfarin due to the 
potential for decreased warfarin efficacy; adjust the dose of warfarin as necessary. Inhibition of 
IL-6 signaling by siltuximab may restore CYP450 activities to higher levels leading to increased 
metabolism of drugs that are CYP450 substrates as compared to metabolism prior to treatment. 
Therefore, CYP450 substrates with a narrow therapeutic index, such as warfarin, may have 
fluctuations in drug levels and therapeutic effect when siltuximab therapy is started or 
discontinued. This effect on CYP450 enzyme activity may persist for several weeks after stopping 
siltuximab. [28549] [57062]
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